Recent advancements in the biotechnology sector highlight a significant development with RetinalGenix Technologies, Inc. leasing a laboratory at the MBC BioLabs incubator in San Carlos, California. This strategic move is set to support the progress of RetinalGenix's innovative Pharmaco-Genetic Mapping platform, aimed at advancing therapies for neurodegenerative and retinal diseases. The facility offers access to cutting-edge scientific equipment and is conveniently located near resources critical for animal research studies. This collaboration also opens potential investment opportunities with Mission BioCapital, fostering further research and therapeutic development in ophthalmic and neurodegenerative fields. Elsewhere in the market, Rockchip Electronics was trading firmly up 10% and closing at CN¥170.47. Meanwhile, Disco softened, down 2.2% to end trading at ¥28,420. AMD's strategic moves in Data Center and AI, alongside the MI350 launch, offer a limited window to explore potential growth narratives. Discover how these opportunities might align with your investment strategy by clicking through to our detailed company narrative. Also, revisit our 'Market Insights' article titled 'Investing In Innovation to Beat Stagflation,' where we highlighted the pivotal role of AI Chips in driving productivity growth amidst economic uncertainty—acting fast could capitalize on these dynamic shifts. Best AI Chip Stocks QUALCOMM ended the day at $139.81 up 3.4%. NVIDIA finished trading at $114.50 up 2.6%. Advanced Micro Devices settled at $98.80 up 2.2%. Taking Advantage Investigate our full lineup of 49 AI Chip Stocks featuring SK hynix, ASML Holding and ASE Technology Holding right here. Want Some Alternatives? We've found 18 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sources: Simply Wall St "RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs" from RetinalGeniX Technologies, Inc. on GlobeNewswire (published 05 May 2025) Story Continues Companies discussed in this article include SHSE:603893 NasdaqGS:QCOMNasdaqGS:NVDANasdaqGS:AMD and TSE:6146. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
This Week In AI Chips - RetinalGenix Gains Ground With New Laboratory Lease
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...